Tag Archives: Bosulif

Another CML win!

Posted on November 29, 2012 by Megan Kilkenny

Like Pfizer’s Bosulif, newly approved Synribo (from Teva Pharmaceuticals) gives CML patients options. As I mentioned in my September post about Bosulif, CML patients have a specific type of genetic mutation called the Philadelphia chromosome. This mutation causes bone marrow to make an enzyme … Continue reading →

Rate this:

Posted in Blood Cancer Research | Tagged , , | Leave a comment

New Pfizer drug brings hope to CML patients

Posted on September 8, 2012 by Megan Kilkenny

Over the past several years, LLS has been working hard to get new therapies to patients with some of the rarer forms of blood cancer. So it’s nice to see the FDA approve a new drug that aligns so well … Continue reading →

Rate this:

Posted in General SF Chapter | Tagged , , | 1 Comment